As of 2026-01-05, the EV/EBITDA ratio of Sigilon Therapeutics, Inc. (SGTX) is -0.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGTX's latest enterprise value is 32.33 mil USD. SGTX's TTM EBITDA according to its financial statements is -34.77 mil USD. Dividing these 2 quantities gives us the above SGTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.1x - 15.3x | 15.2x |
| Forward P/E multiples | 19.5x - 34.7x | 21.9x |
| Fair Price | (259.99) - (202.20) | (246.85) |
| Upside | -1257.0% - -999.9% | -1198.6% |
| Date | EV/EBITDA |